[Effect of long-acting garlic tablets "allicor" on the incidence of acute respiratory viral infections in children].
OBJECTIVE
To elucidate the prospects administration of allicor (long-releasing garlic tablets) in prevention of acute respiratory diseases (ARD) in children vs benzimidazole (dibazole).


METHODS
At the first stage, tolerance of allicor (600 mg/day) and its effects on ARD morbidity were investigated in an opened 5-month study in 172 children aged 7-16 years compared to 468 controls. As the second stage, the effects of allicor (300 mg/day) on ASRD morbidity were investigated in a double-blind placebo-controlled randomized 5-month trial in 42 children aged 10-12 years in comparison with 41 placebo-treated children and 73 benzimidazole-treated children.


RESULTS
At the first stage of the study allicor was not observed to induce gastrointestinal side effects in children at any dosage while ARD morbidity was reduced 2-4-fold as compared to the controls. At the second stage of the study allicor reduced ARD morbidity 1.7-fold compared to placebo and 2.4-fold vs benzimidazole. There was no significant difference in ARD morbidity between placebo- and benzimidazole-treated groups. Health index in allicor-treated group was 1.5-fold higher as compared either to placebo- or benzimidazole-treated children.


CONCLUSIONS
Thus, the results of this study have demonstrated that allicor is effective for non-specific prevention of acute respiratory infections in children and has no side effects. ARD prevention with benzimidazole appeared ineffective in placebo-controlled study, so the development of new useful and safe preparations is of ultimate importance.
Andrianova
I V
IV
Sobenin
I A
IA
Sereda
E V
EV
Borodina
L I
LI
Studenikin
M I
MI
D000293:Adolescent; D002648:Child; D005737:Garlic; D006801:Humans; D015994:Incidence; D010919:Placebos; D012141:Respiratory Tract Infections / Q000517:prevention & control*; D013607:Tablets; D014777:Virus Diseases / Q000517:prevention & control*
D010919:Placebos; D013607:Tablets
Vliianie chesnochnykh tabletok prolongirovannogo deĭstviia "allikor" na zabolevaemost' ostrymi respiratornymivirusnymi infektsiiami u deteĭ.